Shire plc Release: Dermagraft® Now Available in Canada for the Treatment of Diabetic Foot Ulcers
MONTREAL, March 25, 2013 /CNW Telbec/ - Shire Canada Inc. announced today that DERMAGRAFT (human fibroblast-derived dermal substitute) is now available in Canada for the treatment of diabetic foot ulcers (DFUs) greater than 6 weeks duration, which extend through the dermis, but without tendon, muscle, joint capsule, or bone exposure.